Continental Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Continental Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.55M	Sell	16,200 -1,000	-6%	-$158K	1.09%	30
2026 Q2	$2.72M	Sell	17,200 -10,500	-38%	-$1.42M	1.15%	27
2026 Q1	$3.54M	Hold	27,700	–	–	1.81%	22
2025 Q4	$3.38M	Sell	27,700 -8,500	-23%	-$975K	1.43%	25
2025 Q3	$3.63M	Sell	36,200 -500	-1%	-$45K	1.57%	21
2025 Q2	$3.04M	Buy	36,700 +10,500	+40%	+$838K	1.43%	26
2025 Q1	$2.12M	Hold	26,200	–	–	1.19%	29
2024 Q4	$2.36M	Buy	26,200 +500	+2%	+$48.4K	1.09%	26
2024 Q3	$2.54M	Sell	25,700 -2,500	-9%	-$246K	1.22%	28
2024 Q2	$2.61M	Buy	28,200 +5,000	+22%	+$448K	1.15%	32
2024 Q1	$2.2M	Buy	23,200 +1,500	+7%	+$139K	0.89%	31
2023 Q4	$1.94M	Sell	21,700 -15,500	-42%	-$1.15M	0.76%	37
2023 Q3	$2.72M	Buy	37,200 +1,500	+4%	+$120K	1.45%	28
2023 Q2	$2.97M	Sell	35,700 -6,500	-15%	-$544K	1.34%	25
2023 Q1	$3.22M	Sell	42,200 -3,800	-8%	-$315K	1.72%	21
2022 Q4	$3.82M	Buy	46,000 +18,200	+65%	+$1.47M	2%	18
2022 Q3	$2.2M	Sell	27,800 -5,500	-17%	-$464K	1.3%	33
2022 Q2	$2.47M	Buy	33,300 +300	+0.9%	+$22.5K	1.49%	26
2022 Q1	$2.97M	Buy	+33,000	New	+$3.05M	1.46%	25

Other funds holding XBI

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.91% 1-Year Est. Return

Williams Jones Wealth Management New York $8.94B AUM 17.99% 1-Year Est. Return

Annex Advisory Services Brookfield, Wisconsin $6.11B AUM 13.75% 1-Year Est. Return

Continental Advisors's XBI Position: Q3 2026 in Review

Continental Advisors reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 5.8% in Q3 2026, selling an estimated $158K and leaving 16,200 shares worth $2.55M. The position accounts for 1.09% of the portfolio, ranked #30.

Continental Advisors first reported a position in XBI in Q1 2022 and has held it in 19 quarters since. The position peaked at $3.82M in Q4 2022. 521 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

Continental Advisors held 16,200 shares of State Street SPDR S&P Biotech ETF worth $2.55M as of Q3 2026.
Continental Advisors sold 1,000 State Street SPDR S&P Biotech ETF shares in Q3 2026, an estimated $158K.
State Street SPDR S&P Biotech ETF made up 1.09% of Continental Advisors's portfolio in Q3 2026, its #30 holding.
Continental Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and has held it in 19 quarters since.
Continental Advisors's State Street SPDR S&P Biotech ETF position peaked at $3.82M in Q4 2022.
521 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Continental Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.